New solutions for metabolic dysfunction
1st Dec, 2022

This post is specifically for health practitioners. Create a free account

Alternatively, view general public info.

Learn more about vital.ly

 

Impacting approximately one in five adults, patterns of elevated blood lipids, central adiposity, raised insulin and abnormal glucose reflect metabolic dysfunction (1). Disturbingly, these imbalances can gradually manifest over several years, promoting infertility, immune dysfunction, cognitive decline, cardiovascular disease and more (1,2,3,4). Accordingly, it follows that by supporting metabolic balance practitioners can achieve meaningful impacts in the lives of individuals.

 

Energy overload explained

Human metabolism is made up of cells, tissues and organs connected by signalling pathways that enable the swift absorption of nutritional energy (5). Following absorption, energy is stored as glycogen within skeletal muscle (5). Once glycogen capacity is met, energy is then converted into triglycerides and packaged into lipoprotein transporters, which deposit energy into subcutaneous fat (5). In effect, muscle and body fat act as storage reservoirs that accommodate excess energy, which can be drawn upon in times of need (5). However, in metabolic dysfunction, energy overconsumption beyond reservoir thresholds leads to changes that distort metabolic control (6,7).

 

Storage overload drives metabolic dysfunction

Several factors can influence the body’s ‘holding capacity’ when it comes to stored energy. For example, inadequate exercise, poor nutrition, and ageing diminishes muscle mass, resulting in reduced glycogen metabolism and storage (8,9). In addition, individual body fat thresholds  that differ between men (23%), women (38%) and children (30% to 34%) also impact storage capacity (10,11,12). In metabolic dysfunction, energy intake that exceeds reservoir limits begins to accumulate in organs (7,13,14).

Within these tissues, energy is stored as visceral fat, which has been shown to lower hepatic insulin sensitivity (13). Problematically, this reduces the functional role of insulin that moderates gluconeogenesis  within the liver. Following this, unregulated gluconeogenesis  increases circulating glucose, which triggers greater insulin output. Outside of this, compensatory insulin production stimulates lipid synthesis, which further promotes visceral fat accumulation – driving a vicious cycle of energy overload, visceral fat and hyperinsulinaemia (13).

 

Visceral fat provokes chronic metabolic disease

Observed in approximately 70% of type 2 diabetics (13,15), visceral fat is strongly related to the progression of metabolic dysfunction (7,13,16,17). Described as the ‘twin cycle’ effect (7), research has uncovered the mechanisms through which visceral fat contributes to dysregulated energy metabolism (13). Namely, fat accumulation within the pancreas manifests as an overabundance of fatty acids within cells. This in turn upregulates metabolic processes that produce reactive oxygen species (ROS) (18), which inflict pro-inflammatory damage within pancreatic islet beta cells  (β-cells) (19,20,21). Over time inflammatory damage within the pancreas diminishes β-cell function. Inevitably, this leads to reduced insulin output and the development of type 2 diabetes (13) - highlighting the importance of addressing the twin cycle to preserve metabolic health.

 

Berberine, silymarin and chromium supports metabolic dysfunction

Natural medicines have been shown to improve metabolic pathology and lower visceral fat. Specifically, a unique blend of Berberis aristate (Indian barberry) containing 1,000 mg/day of berberine hydrochloride paired with silymarin extract derived from Silybum marianum (milk thistle) provides enhanced clinical effects (22). Notably, the combination of berberine and silymarin over 6 to 12 months in patients with metabolic dysfunction was shown to:

  • Lower total cholesterol, low-density lipoprotein (LDL) and elevated triglycerides (23,24).
  • Increase high-density lipoprotein (HDL) levels (23,24).
  • Achieve greater lipid-lowering effects compared to metformin treatment (24).
  • Reduce fasting glucose, post prandial glucose, glycated haemoglobin (HbA1c), fasting insulin and insulin resistance comparable to 1,500 mg/day of metformin (24).
  • Achieve a 21.6% greater reduction in visceral fat compared to a placebo in conjunction with a 20%-25% caloric deficit diet and 30 minutes of exercise daily (23).

In addition to these herbs, the essential micronutrient chromium has also been shown to improve glucose control and support weight management (25,26). Therefore, these findings support the therapeutic value of Indian Barberry and Milk Thistle for Blood Glucose Metabolism and Liver Function Support.

 

Let’s talk about stress

Metabolic dysfunction is strongly linked to chronic life stress (27,28), which can sensitise patients to stressful stimuli (29,30) and is associated with insulin resistance (31), hyperglycaemia (32) and overeating behaviours (28). Although exposure to stress is an unavoidable part of life, Practitioners are uniquely positioned to support their patient’s mental wellbeing. By combining the Clinically Effective Stress, Anxiety and Mood Range with strategies that improve diet, lifestyle, social and physical health, practitioners can help to build patient resilience and improve their adaptation to stress.

 

Solutions to combat a chronic health crisis

To support metabolic health, science offers new understandings with promising potential. By addressing the twin cycle, Indian Barberry and Milk Thistle for Blood Glucose Metabolism and Liver Function Support can help lower blood lipids and assist in the normalisation of blood glucose. Combined with enhancing diet quality, encouraging weight loss, promoting physical activity and managing life stress, practitioners can successfully achieve life-changing impacts in clinical practice to promote cardiometabolic wellness.

 

For more information on metabolic health visit metagenicsinstitute.com.au or metagenicsinstitute.co.nz, or contact our Clinical Support team on 1800 777 648 (Australia) or 0508 227 744 (New Zealand).

Loading...
References
1Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the Asia-pacific region: a systematic review. BMC Public Health. 2017 Jan 21;17(1):101.
2Cree-Green M, Rahat H, Newcomer BR, Bergman BC, Brown MS, Coe GV, et al. Insulin resistance, hyperinsulinemia, and mitochondria dysfunction in nonobese girls with polycystic ovarian syndrome. J Endocr Soc. 2017 Jun 1;1(7):931-44.
3Mangone A, Yates KF, Sweat V, Joseph A, Convit A. Cognitive functions among predominantly minority urban adolescents with metabolic syndrome. Appl Neuropsychol Child. 2018 Apr-Jun;7(2):157-63.
4Haase Alasantro L, Hicks TH, Green-Krogmann E, Murphy C. Metabolic syndrome and cognitive performance across the adult lifespan. PLoS One. 2021 May 6;16(5):e0249348.
5Judge A, Dodd MS. Metabolism. Essays Biochem. 2020 Oct 8;64(4):607-47.
6Qiu H, Schlegel V. Impact of nutrient overload on metabolic homeostasis. Nutr Rev. 2018 Sep 1;76(9):693-707.
7Taylor R. Type 2 diabetes and remission: practical management guided by pathophysiology. J Intern Med. 2021 Jun;289(6):754-70.
8Yang J. Enhanced skeletal muscle for effective glucose homeostasis. Prog Mol Biol Transl Sci. 2014;121:133-63.
9Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010 Apr;91(4):1123-27.
10Kelly AS, Kaizer AM, Bosch TA, Rudser KD, Ryder JR, Gross AC, et al. Reaching the tipping point: identification of thresholds at which visceral adipose tissue may steeply increase in youth. Obesity (Silver Spring). 2020 Jan;28(1):139-45.
11Bosch TA, Steinberger J, Sinaiko AR, Moran A, Jacobs DR Jr, Kelly AS, et al. Identification of sex-specific thresholds for accumulation of visceral adipose tissue in adults. Obesity (Silver Spring). 2015 Feb;23(2):375-82.
12Bosch TA, Chow L, Dengel DR, Melhorn SJ, Webb M, Yancey DA, et al. In adult twins, visceral fat accumulation depends more on exceeding sex-specific adiposity thresholds than on genetics. Metabolism. 2015 Sep;64(9):991-8.
13Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 2019 Sep;7(9):726-36.
14Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: an early indicator of metabolic dysfunction. J Endocr Soc. 2019 Jul 24;3(9):1727-47.
15Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008 Mar;51(3):444-50.
16Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019 May;7(5):344-55.
17Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab. 2018 Oct 2;28(4):547-56.
18Sun Y, Yuan X, Zhang F, Han Y, Chang X, Xu X, et al. Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. Sci Rep. 2017 Sep 12;7(1):11340.
19Kahn R, Ferris H, O’neill B. Williams textbook of endocrinology. 14th ed. Philadelphia (USA): Elsevier; 2020. p. 1349-1370.
20Lee JH, Lee J. Endoplasmic reticulum (ER) stress and its role in pancreatic β-cell dysfunction and senescence in type 2 diabetes. Int J Mol Sci. 2022 Apr 27;23(9):4843.
21Zhang Z, Li B, Meng X, Yao S, Jin L, Yang J, et al. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Sci Rep. 2016 Feb 9;6:20848.
22Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013 Nov 19;5:167-74.
23Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G, at al. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Silybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):495-502.
24Derosa G, Gaudio G, D’Angelo A, Maffioli P. Efficacy of Berberis aristata compared to metformin in improving glycemic control and insulin resistance in patients with type 2 diabetes mellitus. J Food Nut Res. 2020;8(4):212-15.
25Farrokhian A, Mahmoodian M, Bahmani F, Amirani E, Shafabakhsh R, Asemi Z. The influences of chromium supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Biol Trace Elem Res. 2020 Apr;194(2):313-30.
26Kim CW, Kim BT, Park KH, Kim KM, Lee DJ, Yang SW, et al. Effects of short-term chromium supplementation on insulin sensitivity and body composition in overweight children: randomized, double-blind, placebo-controlled study. J Nutr Biochem. 2011 Nov;22(11):1030-4.
27Salleh MR. Life event, stress and illness. Malays J Med Sci. 2008 Oct;15(4):9-18.
28Lee C, Tsenkova V, Carr D. Childhood trauma and metabolic syndrome in men and women. Soc Sci Med. 2014 Mar;105:122-30.
29Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012 Feb;36(2):764-85.
30Alcocer-Gómez E, de Miguel M, Casas-Barquero N, Núñez-Vasco J, Sánchez-Alcazar JA, Fernández-Rodríguez A, et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun. 2014 Feb;36:111-7.
31Yan YX, Xiao HB, Wang SS, Zhao J, He Y, Wang W, et al. Investigation of the relationship between chronic stress and insulin resistance in a Chinese population. J Epidemiol. 2016 Jul 5;26(7):355-60.
32Goiato MC, da Silva EVF, Cândido NB, Nóbrega AS, de Medeiros RA, Sumida DH, et al. Evaluation of the level of cortisol, capillary blood glucose, and blood pressure in response to anxiety of patients rehabilitated with complete dentures. BMC Oral Health. 2019 May 3;19(1):75.